Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana

Antiviral Therapy

Volumn 18, Issue 4, 2013, Pages 585-590

  Shapiro, Roger L ^a,b,c   Rossi, Steven ^d   Ogwu, Anthony ^c   Moss, Mary ^d   Leidner, Jean ^c   Moffat, Claire ^c   Lockman, Shahin ^b,c,e   Moyo, Sikhulile ^c   Makhema, Joseph ^c   Essex, Max ^b,c   Capparelli, Edmund ^d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD SAMPLING; BOTSWANA; BREAST MILK; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MATERNAL CARE; MATERNAL PLASMA; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PRENATAL CARE; PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; THIRD TRIMESTER PREGNANCY; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BOTSWANA; BREAST FEEDING; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; LACTATION; LAMIVUDINE; LOPINAVIR; MIDDLE AGED; MILK, HUMAN; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VIRAL LOAD; ZIDOVUDINE;

EID: 84885332778     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2474     Document Type: Article

References (16)

1. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362:2282-2294.
2. Thomas T, Masaba R, Ndivo R, et al. Prevention of motherto-child transmission of HIV-1 among breastfeeding mothers using HAART: The Kisumu Breastfeeding Study, Kisumu, Kenya, 2003-2007. 15th CROI 3-6 February 2008 Boston, MA, USA. Abstract 45aL.B.
3. Kesho Bora Study Group, de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11:171-180.
4. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010; 362:2271-2281.
5. Shapiro RL, Holland DT, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 2005; 192:720-727.
6. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2009; 53:1170-1176.
7. Mirochnick M, Best BM, Stek AM, et al. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2008; 49:485-491.
8. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998; 178:368-374.
9. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20:1931-1939.
10. Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:437-443.
11. Ramautarsing RA, van der Lugt J, Gorowara M, et al. Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy. AIDS 2011; 25:1299-1303.
12. Cressey TR, Jourdain G, Rawangban B, et al. PHPT-5 Team. Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS 2010; 24:2193-2200.
13. Lyons F, Lechelt M, De Ruiter A. Steady-state lopinavir levels in third trimester of pregnancy. AIDS 2007; 21:1053-1054.
14. Bouillon-Pichault M, Jullien V, Azria E, et al. Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment. J Antimicrob Chemother 2009; 63:1223-1232.
15. Else LJ, Douglas M, Dickinson L, Back DJ, Khoo SH, Taylor GP. Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. Antimicrob Agents Chemother 2012; 56:816-824.
16. Kumar PN, Sweet DE, McDowell JA, et al. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 1999; 43:603-608.